Jul 1, 2021

RedHill Biopharma reports preliminary results from new preclinical study showing potent inhibition of COVID-19 variants

Posted by in category: biotech/medical

Preliminary results showed potent inhibition of both the Beta and Gamma variants by opaganib at non-cytotoxic doses, the company said.

Opaganib is a unique host-targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of COVID-19.

Leave a reply